The first patient has now been dosed in IntelGEnx and atai Life Sciences’ Phase 1 clinical trial to investigate buccal VLS-01 – a buccal film containing...
Palo Santo has announced the closing of its USD$50m (~£134.10m) fund which will go towards a diverse portfolio of businesses developing innovative psychedelic medicines and therapies.
Biomind Labs has confirmed that it has had a Pre-Investigational New Drug (Pre-IND) meeting granted by the U.S.
APPA is aiming to integrate psychedelics into the US healthcare system and ensure safe access for all who can benefit from the treatments.
UK-based global nootropics company Puresport has had its Reishi, Cordyceps and Lion’s Mane supplements certified by Informed Sport, the gold-standard independent certification body.
Numinus Wellness is developing an innovative method of delivery for psilocybin in clinical trials and research.
Silo Pharma is embarking on a preclinical toxicity study of its novel time-released, dosage-controlled formulation of ketamine – SP-26 – for the treatment of fibromyalgia.
Researchers from Inserm, CNRS, Sorbonne University and clinicians from the AP-HP and at Paris Brain Institute identified one of the mechanisms explaining ketamine effect as an...
In a groundbreaking move for Canada’s regulatory developments around psychedelics, Alberta has announced it will be introducing quality standards into its Mental Health Services Protection Act...
The clinical trial, carried out by a wholly-owned subsidiary of Creso Pharma Limited, Halucenex Life Sciences Inc.,